Half Year 2019 Roche Holding AG Earnings Call Transcript
Good morning, good afternoon. Thank you for joining our half year briefing. A strong set of results entirely driven by the demand for our new medicines. Based on that, we are even more confident on the continued momentum for the future. We have raised, as you know, the outlook for the current year. We expect to grow in 2020 and beyond through this transition when biosimilars enter also the U.S. market.
Let's get right into the figures. You've seen overall sales up by 9% at constant currencies. Pharma up by 10%, again, driven by the strong demand for new medicines. OCREVUS continues to deliver strong results, HEMLIBRA, very good start. PERJETA in the adjuvant setting, KADCYLA, Tecentriq now in new indications, offsetting the decline we are already experiencing as expected from the entry of biosimilars in Europe.
Diagnostics, 2%, and actually, an acceleration in the second quarter. You remember in the first quarter, we had no growth due to some specific factors. We have now seen 4% growth. So coming back to our continued
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
